Results 51 to 60 of about 1,547 (116)

Pegcetacoplan (Empaveli)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
CDA-AMC
core   +1 more source

One-Year Results of Geographic Atrophy Patients with Pre-Existing nAMD treated with both anti-VEGF therapy and pegcetacoplan.

Purpose: To examine geographic atrophy (GA) progression in patients receiving pegcetacoplan injections with pre-existing neovascular age-related macular degeneration (nAMD) treated previously and concurrently with
Sean D. Adrean, Jonathan Hui, Ash Pirouz, Wesley Han   +3 more
core   +1 more source

Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.

PLoS ONE
BackgroundAlthough complement component 5 inhibitors (C5is) eculizumab and ravulizumab improve paroxysmal nocturnal hemoglobinuria (PNH) outcomes, patients may experience persistent anemia.
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, Mohammed Al-Adhami, Emmelie Persson, Raymond Siu Ming Wong   +8 more
doaj   +1 more source

Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials

Frontiers in Pharmacology
ImportanceClinical trials in recent years have shown significant effectiveness of complement inhibitors for geographic atrophy (GA) treatment. Two complement inhibitor drugs have been approved by the Food and Drug Administration (FDA).Objectiveto compare
Huan Wang, Jiaqi Zheng, Qing Zhang, Zhongping Tian, Yuhang Sun, Tianyi Zhu, Yanlong Bi, Yanlong Bi, Li Zhang, Li Zhang   +9 more
doaj   +1 more source

Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review

Ophthalmology and Therapy
Rationale In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration.
Anne Helene Køllund Nissen, Thomas Lee Torp, Anna Stage Vergmann   +2 more
doaj   +1 more source

PNH TREATMENT: TREATMENTS OF TODAY AND TOMORROW

Hematology, Transfusion and Cell Therapy
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder characterized by chronic destruction of red blood cells (hemolytic anemia) and blood clots (thrombosis).1 PNH can occur at any age, although it is most often diagnosed in young ...
Zeynep Tuğba Güven
doaj   +1 more source

Anti-complement drugs for the treatment of geographic atrophy and the release of silicone oil

International Journal of Retina and Vitreous
Intravitreal injections are a common procedure in ophthalmology, often using syringes coated with silicone to aid piston movement and needles coated with silicone oil to facilitate penetration of the sclera. Pegcetacoplan and avacincaptad pegol, recently
Gustavo Barreto Melo, Geoffrey Guy Emerson   +1 more
doaj   +1 more source

Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies

Indian Journal of Ophthalmology
The age-related macular degeneration (AMD) field is witnessing promising advancements in therapeutic options. Breakthrough drugs such as pegcetacoplan and avacincaptad have been FDA-approved for dry AMD, marking a significant development as there were no
Audrey Yan, Nasiq Hasan, Jay Chhablani
doaj   +1 more source

The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment

Turkish Journal of Hematology
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare chronic bone marrow failure condition characterized by complement-mediated hemolytic anemia and thrombosis.
Cameron Perry, Xinyu Von Buttlar, Swapna Thota   +2 more
doaj   +1 more source

Dry Age-related Macular Degeneration: Not So Dry Today!!

Delhi Journal of Ophthalmology
Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in people over 55 years, driven by age-related changes in the retinal pigment epithelium, Bruch’s membrane, and choriocapillaris that impair waste clearance and
Bhanu Priya, Lalit Verma, Priksha Lakhlan, Avnindra Gupta   +3 more
doaj   +1 more source